No Data
Sirio Pharma (300791): Channel structure adjustment hinders the pace of business in China, but the long-term trend of optimizing leading pattern remains unchanged.
The event describes Sirio Pharma's announcement of the third quarter report for 2024. The company's total operating income for Q1-3 2024 is 3.048 billion yuan (+21.8% year-on-year); net income attributable to the parent company is 0.24 billion yuan (+29.52% year-on-year), after deducting non-recurring items.
Sirio Pharma (605338): Leading ODM in health supplements, integrating internal and external growth.
In 2024, the third quarter income increased by 10.4% year-on-year. The total operating income for the first three quarters of 2024 reached 3.048 billion yuan, an increase of 21.80% year-on-year; achieving a net income attributable to the parent company of 0.24 billion yuan, an increase of 29.52% year-on-year.
Sirio Pharma (300791): Sequential decrease in speed, regional differentiation.
Sirio Pharma released the Q3 report for 2024, with the company achieving an income of 3.048 billion yuan in the first three quarters of 2024, a year-on-year increase of 21.80%, and achieving a net income attributable to the parent company of 0.24 billion yuan, a year-on-year increase of 29.52%. Income
Sirio Pharma (300791): Rapid expansion in overseas markets in Q3 24, enhancing global competitiveness
Event: The company released the third quarter report for 2024, achieving revenue of 3.048 billion yuan in the first three quarters of 2024, a year-on-year increase of +21.80%; achieving a net income attributable to the parent company of 0.24 billion yuan, a year-on-year increase of +29.52%;
Sirio Pharma (300791): Domestic weak demand dragging down overall performance, overseas continues high growth momentum report title
Event: The company released its third quarter report for 2024, achieving revenue of 3.048 billion yuan in the first three quarters of 2024, a year-on-year increase of 21.80%; net income attributable to shareholders was 0.24 billion yuan, an increase of +29.52%; adjusted net income 2.
Sirio Pharma (300791): Sprinting to stimulate target, focusing on brand and improvements in China region.
Event: The company released the third quarter report of 2024, achieving revenue of 3.05 billion yuan in the first three quarters, a year-on-year increase of +21.8%; achieving a net income attributable to the parent company of 0.24 billion yuan, a year-on-year increase of +29.5%; achieving a non-net profit attributable to the parent company of 0.24 billion yuan.
No Data
No Data